JP4162991B2 - Ｎｍｄａ受容体リガンドに対するプロドラッグ - Google Patents

Ｎｍｄａ受容体リガンドに対するプロドラッグ Download PDF

Info

Publication number
JP4162991B2
JP4162991B2 JP2002521197A JP2002521197A JP4162991B2 JP 4162991 B2 JP4162991 B2 JP 4162991B2 JP 2002521197 A JP2002521197 A JP 2002521197A JP 2002521197 A JP2002521197 A JP 2002521197A JP 4162991 B2 JP4162991 B2 JP 4162991B2
Authority
JP
Japan
Prior art keywords
formula
compound
hydroxy
benzyl
ethanesulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002521197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004506715A5 (https=
JP2004506715A (ja
Inventor
アラニン，アレキザンダー
ビュッテルマン，ベルント
フィッシャー，ホルガー
ハイツ・ニダール，マリー−ポール
フヴィラー，イェルク
ヤーシュケ，ゲオルク
ピナール，エマニュエル
ワイラー，レネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004506715A publication Critical patent/JP2004506715A/ja
Publication of JP2004506715A5 publication Critical patent/JP2004506715A5/ja
Application granted granted Critical
Publication of JP4162991B2 publication Critical patent/JP4162991B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002521197A 2000-08-21 2001-08-20 Ｎｍｄａ受容体リガンドに対するプロドラッグ Expired - Fee Related JP4162991B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
PCT/EP2001/009561 WO2002016321A1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Publications (3)

Publication Number Publication Date
JP2004506715A JP2004506715A (ja) 2004-03-04
JP2004506715A5 JP2004506715A5 (https=) 2005-03-17
JP4162991B2 true JP4162991B2 (ja) 2008-10-08

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002521197A Expired - Fee Related JP4162991B2 (ja) 2000-08-21 2001-08-20 Ｎｍｄａ受容体リガンドに対するプロドラッグ

Country Status (35)

Country Link
US (1) US6407235B1 (https=)
EP (1) EP1313703B1 (https=)
JP (1) JP4162991B2 (https=)
KR (1) KR100589991B1 (https=)
CN (1) CN1227230C (https=)
AR (1) AR030373A1 (https=)
AT (1) ATE386022T1 (https=)
AU (2) AU8589401A (https=)
BR (1) BR0113348A (https=)
CA (1) CA2419279C (https=)
CY (1) CY1107937T1 (https=)
CZ (1) CZ303319B6 (https=)
DE (1) DE60132782T2 (https=)
DK (1) DK1313703T3 (https=)
EC (1) ECSP034489A (https=)
EG (1) EG24293A (https=)
ES (1) ES2299508T3 (https=)
HR (1) HRP20030125B1 (https=)
HU (1) HU229802B1 (https=)
IL (1) IL154254A0 (https=)
JO (1) JO2289B1 (https=)
MA (1) MA26947A1 (https=)
MX (1) MXPA03001311A (https=)
MY (1) MY136065A (https=)
NO (1) NO324941B1 (https=)
NZ (1) NZ523990A (https=)
PA (1) PA8525601A1 (https=)
PE (1) PE20020291A1 (https=)
PL (1) PL204215B1 (https=)
PT (1) PT1313703E (https=)
RS (1) RS51467B (https=)
RU (1) RU2272027C2 (https=)
SI (1) SI1313703T1 (https=)
WO (1) WO2002016321A1 (https=)
ZA (1) ZA200300894B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1265864A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CA2633010A1 (en) * 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
EP1973872A4 (en) 2006-12-19 2012-05-09 Methylgene Inc HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF
PL4001272T3 (pl) 2013-11-05 2025-02-10 Astrazeneca Ab Proleki antagonisty nmda

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
KR100589991B1 (ko) 2006-06-15
US6407235B1 (en) 2002-06-18
JO2289B1 (en) 2005-09-12
CY1107937T1 (el) 2013-09-04
RS51467B (sr) 2011-04-30
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28
HRP20030125A2 (en) 2005-02-28
ES2299508T3 (es) 2008-06-01
PE20020291A1 (es) 2002-04-17
DE60132782T2 (de) 2009-02-05
SI1313703T1 (sl) 2008-06-30
CZ303319B6 (cs) 2012-08-01
MY136065A (en) 2008-08-29
PL204215B1 (pl) 2009-12-31
NO20030781D0 (no) 2003-02-19
EP1313703A1 (en) 2003-05-28
AR030373A1 (es) 2003-08-20
KR20030022417A (ko) 2003-03-15
PT1313703E (pt) 2008-03-25
AU2001285894B2 (en) 2006-06-15
EG24293A (en) 2009-01-08
BR0113348A (pt) 2003-07-08
DK1313703T3 (da) 2008-05-19
HRP20030125B1 (en) 2011-07-31
ATE386022T1 (de) 2008-03-15
MXPA03001311A (es) 2003-06-30
EP1313703B1 (en) 2008-02-13
HUP0301548A2 (hu) 2003-08-28
AU8589401A (en) 2002-03-04
IL154254A0 (en) 2003-09-17
DE60132782D1 (de) 2008-03-27
CN1227230C (zh) 2005-11-16
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
CA2419279C (en) 2008-10-14
MA26947A1 (fr) 2004-12-20
CZ2003492A3 (cs) 2004-01-14
NO20030781L (no) 2003-02-19
PA8525601A1 (es) 2002-04-25
JP2004506715A (ja) 2004-03-04
US20020040037A1 (en) 2002-04-04
WO2002016321A1 (en) 2002-02-28
ZA200300894B (en) 2004-04-30
ECSP034489A (es) 2003-03-31
RU2272027C2 (ru) 2006-03-20
CA2419279A1 (en) 2002-02-28
PL361387A1 (en) 2004-10-04
NZ523990A (en) 2004-09-24
CN1447793A (zh) 2003-10-08
HUP0301548A3 (en) 2010-03-29

Similar Documents

Publication Publication Date Title
EA034922B1 (ru) Соединения и их применения для модуляции гемоглобина
JP2010521453A (ja) 新規プロドラッグ
JP4162991B2 (ja) Ｎｍｄａ受容体リガンドに対するプロドラッグ
CA2819106C (en) Kat ii inhibitors
JPH08503229A (ja) Ｇａｂａ−ｂアンタゴニストとしての２−置換モルホリンおよびチオモルホリン誘導体
AU2001285894A1 (en) Prodrugs to NMDA receptor ligands
CN117384091B (zh) 一类酰胺衍生物、合成方法及用途
WO1995025100A1 (fr) Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes
EP1275641B1 (fr) Dérivés de benzène sulfonamide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
RU2610276C1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
KR20010033998A (ko) 신경학적 질병 치료용 1,4-디아자시클로헵탄 유도체
EP0508004A1 (en) Phenylsulfonylalkanoic acid compounds
FR2717174A1 (fr) Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
FR2488892A2 (fr) Nouveaux derives 1-(3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl)-4-aryl-piperaziniques, procede pour leur preparation et leur application en tant que medicament

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080715

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080723

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110801

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110801

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120801

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130801

Year of fee payment: 5

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees